Vistagen To Present Fasedienol Safety And Exploratory Efficacy Data From Phase 3 Open-Label Social Anxiety Disorder Study At American Society For Clinical Psychopharmacology Annual Meeting
Portfolio Pulse from Happy Mohamed
Vistagen (NASDAQ: VTGN) will present safety and exploratory efficacy data from its Phase 3 open-label study of fasedienol nasal spray for the treatment of adults with social anxiety disorder at the American Society for Clinical Psychopharmacology Annual Meeting. Fasedienol is a first-in-class, rapid-onset investigational pherine nasal spray with a novel mechanism of action.
May 30, 2023 | 8:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vistagen will present Phase 3 data on fasedienol nasal spray for social anxiety disorder, potentially transforming the treatment landscape for anxiety and depression.
The presentation of positive Phase 3 data on fasedienol nasal spray at the ASCP Annual Meeting could potentially boost investor confidence in Vistagen's product pipeline and its ability to transform the treatment landscape for anxiety and depression. This may lead to a short-term positive impact on VTGN's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100